Previous 10 | Next 10 |
AbCellera (ABCL) announces that Neil Berkley has been appointed as the company's chief business officer ((CBO)).Berkley has more than 20 years of strategic planning and corporate and business development experience across a wide range of transactions and therapeutic indica...
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley’s role will include leading the strategy and continued ...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Stanley Druckenmiller’s 13F portfolio value increased from $3.71B to $3.89B this quarter. Duquesne added Citigroup and Palantir Technologies while dropping Walt Disney. The top three positions are at 25% of the portfolio. For further details see: Tracking Stanley ...
Gemini Therapeutics (GMTX) -31% after initial data from mid-stage GEM103 AMD study.Second Sight Medical Products (EYES) -18% after secures $50M capital via equity raiseTorchlight Energy Resources (TRCH) -17%.Alfi (ALF) -16% stock pulls back from buyback-fueled ra...
AbCellera ([[ABCL]] -3.0%) has secured a site in Vancouver, Canada for the construction of a Good Manufacturing Practices ((GMP)) manufacturing facility for the production of therapeutic antibodies.The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new an...
130,000-square-foot Vancouver facility aims to accelerate the development of antibody-based therapies for an array of medical conditions. AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) ...
Palantir has invested in 6 SPACs over the past year. Each of these innovative investment companies is seeking to use data to disrupt massive industries. I dive into each of these investments, the opportunity they represent, and why Palantir invested in them. For further deta...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
AbCellera (ABCL) rises 0.72% during market after hours with announcement that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, CEO, and President and other senior leaders enter into separate share purchase agreements with ...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
AbCellera Biologics Inc. Website:
AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...
2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...